Therapeutic Asset Ratings

831 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ontorpacept B-Cell Non-Hodgkin Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Diffuse Large B-Cell Lymphoma With Chronic Inflammation	Mayo Clinic	P2	CCC (53)
Ontorpacept Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Diffuse Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Follicular Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept High Grade B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)
Ontorpacept Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)
Ontorpacept Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	Mayo Clinic	P2	CCC (53)
Ontorpacept Primary Mediastinal Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept T-Cell/Histiocyte Rich Large B Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit	Mayo Clinic	P2	CCC (53)
Ontorpacept Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)
Pembrolizumab High Grade Astrocytic Tumor	Mayo Clinic	P2	CCC (53)
Pembrolizumab Astrocytoma, IDH-Mutant, Grade 4	Mayo Clinic	P2	CCC (53)
Pembrolizumab ALK-Positive Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Pembrolizumab Diffuse Large B-Cell Lymphoma With Chronic Inflammation	Mayo Clinic	P2	CCC (53)
Pembrolizumab Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)
Pembrolizumab Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)
Pembrolizumab Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Pembrolizumab Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	Mayo Clinic	P2	CCC (53)
Pembrolizumab High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit	Mayo Clinic	P2	CCC (53)
Pembrolizumab Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	Mayo Clinic	P2	CCC (53)

Showing 426 to 450 of 831 assets

PreviousPage 18 of 34Next